Description: Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.
Home Page: www.ensysce.com
7946 Ivanhoe Avenue
La Jolla,
CA
92037
United States
Phone:
858 263 4196
Officers
| Name | Title |
|---|---|
| Dr. D. Lynn Kirkpatrick Ph.D. | President, CEO & Director |
| Mr. David C. Humphrey CPA | CFO, Secretary & Treasurer |
| Mr. Geoffrey Birkett | Chief Commercial Officer |
| Dr. Jeffrey Millard Ph.d. | Chief Operating Officer |
| Dr. William K. Schmidt Ph.D. | Chairman of Clinical Advisory Board & Chief Medical Officer |
| Dr. Linda Pestano Ph.D. | Chief Development Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |